HIV gel trial targets anal cancer risk
NCT ID NCT05334004
First seen Feb 11, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This early-stage study tests the safety of a gel made from HIV medications (lopinavir/ritonavir) applied inside the anus. It is for people with HIV who have high-grade anal pre-cancerous lesions (AIN 2/3). About 21 participants will use the gel for 3 months and be followed for 40 weeks to check for side effects and whether the lesions shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE ANAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Digestive Health Center Anoscopy Clinic
RECRUITINGMadison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.